Corient Private Wealth LP Takes $5.32 Million Position in Zimmer Biomet Holdings, Inc. $ZBH

Key Points

• Corient Private Wealth acquired 61,790 Zimmer Biomet shares worth approximately $5.32 million in the second quarter. Institutional investors collectively own 88.89% of the company.
• Zimmer Biomet exceeded quarterly expectations, reporting $2.07 in EPS versus the $2.01 consensus and revenue of $2.18 billion, up 4.8% year over year. Management’s fiscal 2026 EPS guidance is $8.47–$8.59.
• The company declared a quarterly dividend of $0.24 per share, equivalent to an annualized $0.96 payout and a 1.0% yield. Analysts maintain a consensus Hold rating with an average price target of $104.42.

Corient Private Wealth LP purchased a new stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) in the 2nd quarter, according to the company in its most recent filing with the SEC. The institutional investor purchased 61,790 shares of the medical equipment provider's stock, valued at approximately $5,320,000.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. DV Equities LLC purchased a new stake in shares of Zimmer Biomet in the fourth quarter valued at about $25,000. Tacita Capital Inc purchased a new position in shares of Zimmer Biomet during the second quarter worth about $26,000. Monetary Solutions Ltd purchased a new position in shares of Zimmer Biomet during the fourth quarter worth about $30,000. Ancora Advisors LLC acquired a new position in Zimmer Biomet in the 2nd quarter valued at about $29,000. Finally, Gen Wealth Partners Inc purchased a new stake in Zimmer Biomet during the 4th quarter valued at approximately $31,000. 88.89% of the stock is owned by hedge funds and other institutional investors.

Zimmer Biomet Price Performance

Zimmer Biomet stock opened at $100.19 on Tuesday. The company has a market cap of $19.11 billion, a P/E ratio of 24.38, a price-to-earnings-growth ratio of 2.74 and a beta of 0.45. Zimmer Biomet Holdings, Inc. has a one year low of $79.12 and a one year high of $106.88. The business has a fifty day moving average of $94.14 and a two-hundred day moving average of $91.52. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.94 and a current ratio of 1.69.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last posted its quarterly earnings results on Wednesday, August 5th. The medical equipment provider reported $2.07 earnings per share for the quarter, topping analysts' consensus estimates of $2.01 by $0.06. The business had revenue of $2.18 billion for the quarter, compared to analysts' expectations of $2.13 billion. Zimmer Biomet had a net margin of 9.48% and a return on equity of 13.12%. The business's revenue for the quarter was up 4.8% on a year-over-year basis. During the same period in the prior year, the company posted $2.07 EPS. Zimmer Biomet has set its FY 2026 guidance at 8.470-8.590 EPS. As a group, analysts predict that Zimmer Biomet Holdings, Inc. will post 8.54 earnings per share for the current fiscal year.

Zimmer Biomet Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, October 30th. Shareholders of record on Wednesday, September 30th will be given a dividend of $0.24 per share. This represents a $0.96 annualized dividend and a yield of 1.0%. The ex-dividend date is Wednesday, September 30th. Zimmer Biomet's dividend payout ratio is presently 23.36%.

Wall Street Analyst Weigh In

Several research analysts have weighed in on ZBH shares. Zacks Research upgraded Zimmer Biomet from a "strong sell" rating to a "hold" rating in a research note on Tuesday, August 25th. Truist Financial upped their price target on Zimmer Biomet from $92.00 to $106.00 and gave the stock a "hold" rating in a research note on Thursday, August 6th. Robert W. Baird set a $104.00 price target on Zimmer Biomet in a report on Thursday, August 6th. UBS Group reiterated a "buy" rating and issued a $120.00 price objective on shares of Zimmer Biomet in a research report on Thursday, August 6th. Finally, Wall Street Zen cut shares of Zimmer Biomet from a "buy" rating to a "hold" rating in a research note on Saturday, August 8th. One analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, fourteen have given a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of "Hold" and a consensus target price of $104.42.

Zimmer Biomet Profile

Zimmer Biomet NYSE: ZBH is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company's product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source